Exelixis, Inc.  

(Public, NASDAQ:EXEL)   Watch this stock  
Find more results for EXEL
3.09
-0.05 (-1.59%)
Real-time:   10:42AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.07 - 3.14
52 week 1.26 - 4.55
Open 3.14
Vol / Avg. 304,006.00/3.72M
Mkt cap 605.40M
P/E     -
Div/yield     -
EPS -1.17
Shares 195.92M
Beta 2.69
Inst. own 63%
Jul 29, 2015
Q2 2015 Exelixis Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 27, 2015
Exelixis Inc Annual Shareholders Meeting - 11:00AM EDT - Add to calendar
May 12, 2015
Exelixis Inc at Bank of America Merrill Lynch Health Care Conference
Apr 30, 2015
Q1 2015 Exelixis Inc Earnings Call - Webcast
Apr 30, 2015
Q1 2015 Exelixis Inc Earnings Release
Mar 3, 2015
Exelixis Inc at Cowen Health Care Conference - Webcast
Feb 24, 2015
Q4 2014 Exelixis Inc Earnings Call - Webcast
Feb 24, 2015
Q4 2014 Exelixis Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -374.63% -1069.42%
Operating margin -242.44% -893.86%
EBITD margin - -854.00%
Return on average assets -46.18% -64.61%
Return on average equity - -
Employees 98 -
CDP Score - -

Address

210 E Grand Ave
SOUTH SAN FRANCISCO, CA 94080-4811
United States - Map
+1-650-8377000 (Phone)
+1-650-8378300 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Exelixis, Inc., is a biotechnology company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources, development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Company’s programs include: COMETRIQ, Cobimetinib Collaboration, and Other Collaborations. COMETRIQ, potential active anti-cancer agent and treats progressive, metastatic MTC and has therapeutic potential, as well as inhibits the activity of multiple tyrosine kinases, including RET, MET, and VEGFR2. Cobimetinib Collaboration, co-development agreement for the development and commercialization of cobimetinib which is an inhibitor of MEK, a serine threonine kinase. Other Collaborations, has established collaborations with pharmaceutical and biotechnology companies for compounds and programs.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Michael M. Morrissey Ph.D. President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Peter Lamb Ph.D. Executive Vice President - Discovery Research, Chief Scientific Officer
Age: 53
Bio & Compensation  - Reuters
Jeffrey J Hessekiel Executive Vice President, General Counsel
Age: 45
Bio & Compensation  - Reuters
Gisela M. Schwab M.D. Executive Vice President, Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Pamela A. Simonton J.D. Executive Vice President
Age: 64
Bio & Compensation  - Reuters
Deborah Burke Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Controller
Age: 59
Bio & Compensation  - Reuters
Charles M. Cohen Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Carl B. Feldbaum Esq Independent Director
Age: 71
Bio & Compensation  - Reuters
Alan M. Garber M.D., Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters